Drug:
Reaction: ILLNESS
20250101 - 20251231
No. 701 - 800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 701 | 25066678 |
CA |
2 | |
Pneumonia, Arthritis, Ear infection, Illness, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CYCLOBENZAPRINE, GABAPENTIN, DULOXETINE HYDROCHLORIDE, PREDNISONE, |
||||
| 702 | 25066696 |
US |
28 | 2 |
Incorrect dose administered, Illness, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 703 | 25067333 |
CA |
36 | 1 |
Abdominal hernia, Allergy to animal, Anxiety, Balance disorder, Blood pressure increased, Cardiac disorder, Cough, Decreased appetite, Erythema, Eye pruritus, Headache, Heart rate decreased, Hypoaesthesia, Illness, Labyrinthitis, Meniscus injury, Mobility decreased, Muscle rupture, Otitis media, Pain, Product dose omission issue, Productive cough, SARS-CoV-2 test positive, Secretion discharge, Sneezing, Spinal pain, Stress, Throat irritation, Vertigo positional, Weight decreased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, PREDNISONE, PREDNISONE, MONTELUKAST SODIUM, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 704 | 25067643 |
US |
87 | 1 |
Illness, |
||||
NIVOLUMAB AND RELATLIMAB-RMBW, |
||||
| 705 | 25067819 |
US |
||
Illness, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 706 | 25067863 |
CA |
58 | 2 |
Abdominal pain, Abdominal pain lower, Blood pressure abnormal, Body temperature decreased, Bone pain, Breast cancer, Drug hypersensitivity, Ear swelling, Erythema, Headache, Illness, Joint stiffness, Oropharyngeal pain, Papule, Paraesthesia, Pruritus, Quality of life decreased, Rubber sensitivity, Sensitive skin, Skin exfoliation, Skin lesion, Skin plaque, Stress, Urticaria, Wound, Inappropriate schedule of product administration, Incorrect dose administered, Product availability issue, Product container issue, Product dose omission issue, Therapeutic response decreased, Therapy partial responder, |
||||
NAPROXEN, NAPROXEN SODIUM, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, HYDROXYZINE, |
||||
| 707 | 25068295 |
US |
1 | |
Illness, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 708 | 25068327 |
US |
1 | |
Illness, |
||||
DUPILUMAB, |
||||
| 709 | 25068453 |
US |
2 | |
Illness, Vomiting, Feeling hot, Product storage error, Headache, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 710 | 25068539 |
CA |
35 | 2 |
Rheumatoid arthritis, Illness, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, HYDROXYCHLOROQUINE SULFATE, |
||||
| 711 | 25068740 |
US |
2 | |
Polymyalgia rheumatica, Loss of personal independence in daily activities, Pain, Illness, |
||||
SARILUMAB, |
||||
| 712 | 25068842 |
CN |
1 | |
Illness, Off label use, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 713 | 25068894 |
US |
62 | 2 |
Illness, |
||||
SARILUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, INSULIN GLARGINE, INSULIN ASPART, ALPRAZOLAM, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, MONTELUKAST SODIUM, MONTELUKAST, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, PREDNISONE, LOSARTAN POTASSIUM, LOSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, ANASTROZOLE, ANASTROZOLE TABLETS, DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, IRON, DOXYCYCLINE, DOXYCYCLINE HYCLATE, ROSUVASTATIN CALCIUM, EZETIMIBE, |
||||
| 714 | 25068954 |
US |
1 | |
Illness, |
||||
DUPILUMAB, |
||||
| 715 | 25069123 |
US |
||
Migraine, Asthenia, Illness, Headache, Dizziness, Product adhesion issue, |
||||
SCOPOLAMINE, |
||||
| 716 | 25069740 |
US |
59 | 1 |
Pneumonia, Staphylococcal infection, Mobility decreased, Fatigue, Illness, Dyspnoea, Cough, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, LISINOPRIL, |
||||
| 717 | 25069775 |
CO |
2 | |
Leukocytosis, Bronchitis, White blood cell count increased, Product intolerance, Influenza, Decreased immune responsiveness, Acne, Headache, General physical health deterioration, Psoriasis, Illness, Hidradenitis, Condition aggravated, Malaise, Breast discomfort, Vulvovaginal discomfort, Drug ineffective, Pruritus, Inflammation, Axillary pain, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 718 | 25069839 |
US |
||
Illness, |
||||
POTASSIUM NITRATE AND SODIUM FLUORIDE, POTASSIUM NITRATE, SODIUM FLUORIDE, STANNOUS FLUORIDE, POTASSIUM NITRATE, |
||||
| 719 | 25069861 |
CA |
55 | 2 |
Aphonia, Bronchitis, Bronchospasm, COVID-19, Drug hypersensitivity, Illness, Occupational exposure to dust, Perfume sensitivity, Pneumonia, Sensitivity to weather change, Throat clearing, Upper respiratory tract infection, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, BUDESONIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 720 | 25069920 |
US |
||
Vomiting, Diarrhoea, Illness, Injection site erythema, |
||||
| 721 | 25070020 |
US |
16 | 2 |
Blood glucose increased, Sleep disorder, Illness, Product dose omission issue, |
||||
DORNASE ALFA, LANSOPRAZOLE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, |
||||
| 722 | 25070109 |
US |
12 | 1 |
Illness, |
||||
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE, |
||||
| 723 | 25070144 |
US |
||
Pneumonia, Seizure, Illness, |
||||
GANAXOLONE, |
||||
| 724 | 25070376 |
US |
||
Illness, |
||||
TIRZEPATIDE, |
||||
| 725 | 25070413 |
CA |
59 | 2 |
Accidental exposure to product, Exposure to SARS-CoV-2, Exposure via skin contact, Gastroenteritis listeria, Illness, Immunodeficiency, Intentional dose omission, Pruritus, Rash, Systemic lupus erythematosus, Urinary tract infection, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, FOLIC ACID, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, MONTELUKAST, NAPROXEN, NAPROXEN SODIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 726 | 25070435 |
CA |
2 | |
Rheumatoid arthritis, Illness, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, HYDROXYCHLOROQUINE, BISOPROLOL FUMARATE, IRBESARTAN, |
||||
| 727 | 25070492 |
US |
3 | 2 |
Illness, |
||||
DUPILUMAB, |
||||
| 728 | 25070504 |
US |
40 | 2 |
Asthma, Illness, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 729 | 25070654 |
US |
40 | 2 |
Illness, |
||||
DUPILUMAB, |
||||
| 730 | 25070655 |
US |
70 | 1 |
Illness, Dyspnoea, |
||||
DUPILUMAB, PREDNISONE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 731 | 25070703 |
US |
71 | 2 |
COVID-19, Illness, Dyspnoea, Condition aggravated, Injury, Accidental exposure to product, Exposure via skin contact, Limb injury, |
||||
DUPILUMAB, |
||||
| 732 | 25070753 |
US |
47 | 2 |
Nasopharyngitis, Cough, Illness, Dysphagia, Secretion discharge, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 733 | 25070870 |
US |
1 | |
Illness, Eosinophilic oesophagitis, |
||||
DUPILUMAB, |
||||
| 734 | 25070898 |
US |
85 | 2 |
Head injury, Illness, Accident, |
||||
UPADACITINIB, |
||||
| 735 | 25070933 |
CA |
2 | |
Hypokalaemia, General physical health deterioration, Dysstasia, Gait disturbance, Grip strength decreased, C-reactive protein increased, Illness, Decreased appetite, Asthenia, Fatigue, Pain, Nausea, Drug ineffective, |
||||
HYDROXYCHLOROQUINE, METHOTREXATE, METHOTREXATE SODIUM, SULFASALAZINE, CELECOXIB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, NAPROXEN, NAPROXEN SODIUM, HYDROXYCHLOROQUINE SULFATE, |
||||
| 736 | 25070992 |
CA |
43 | 2 |
Abdominal pain, Anaemia, Asthma, Benign uterine neoplasm, Blood iron decreased, Blood pressure systolic decreased, Bruxism, COVID-19, Cough, Discomfort, Dizziness, Drug ineffective, Ear pain, Fatigue, Feeling cold, Headache, Heart rate increased, Hypertension, Illness, Incorrect dose administered, Infection, Influenza, Kidney infection, Menstrual disorder, Mucosal discolouration, Nasopharyngitis, Nausea, Oropharyngeal pain, Pain, Pain in jaw, Peripheral swelling, Pneumonia, Productive cough, Pyrexia, Serum ferritin decreased, Sinusitis, Somnolence, Swelling, Temporomandibular pain and dysfunction syndrome, Urinary tract infection, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, CANDESARTAN, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, MOMETASONE FUROATE, PREDNISONE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 737 | 25071078 |
US |
6 | 2 |
Illness, |
||||
DUPILUMAB, |
||||
| 738 | 25071141 |
US |
52 | 2 |
Respiratory arrest, Headache, Fatigue, Pruritus, Anxiety, Hypotension, Dizziness, Cold sweat, Confusional state, Illness, Pain in extremity, Nausea, Skin burning sensation, Drug ineffective, Dyspepsia, Malaise, Abdominal distension, Feeling hot, Dry mouth, Visual impairment, Flushing, Dry skin, Diarrhoea, Neck pain, Hypoaesthesia, Inflammation, Pyrexia, Decreased appetite, Hypoaesthesia oral, Sinus disorder, Dysphagia, Angina pectoris, Head discomfort, Joint range of motion decreased, Somnolence, |
||||
UPADACITINIB, |
||||
| 739 | 25071492 |
US |
2 | |
Pneumonia, Illness, Inappropriate schedule of product administration, Jugular vein thrombosis, Hereditary angioedema, |
||||
ICATIBANT ACETATE, ICATIBANT ACETATE, |
||||
| 740 | 25071517 |
BR |
52 | 2 |
Syncope, Dizziness, Hormone level abnormal, Blood cholesterol increased, Illness, Asthenia, Somnolence, Product odour abnormal, |
||||
LEVOTHYROXINE SODIUM, |
||||
| 741 | 25071533 |
US |
60 | 2 |
Systemic lupus erythematosus, Illness, |
||||
UPADACITINIB, |
||||
| 742 | 25073782 |
81 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 743 | 25061279 |
US |
80 | 2 |
Device difficult to use, Injection site pain, Illness, Influenza like illness, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 744 | 25061486 |
US |
79 | 2 |
Illness, |
||||
TOCILIZUMAB, |
||||
| 745 | 25061503 |
CA |
64 | 1 |
Illness, Lung disorder, Lymphadenopathy, Nasopharyngitis, White blood cell count increased, Rash, |
||||
MEPOLIZUMAB, IPRATROPIUM BROMIDE, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 746 | 25061727 |
CA |
39 | 2 |
Drug hypersensitivity, Illness, Skin plaque, Rebound effect, Stress, Urticaria, Product dose omission issue, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, LORATADINE, LORATADINE TABLET, METRONIDAZOLE, METRONIDAZOLE TOPICAL, |
||||
| 747 | 25061937 |
CA |
58 | 2 |
Aphonia, Arthralgia, Asthma, Body temperature decreased, Chest discomfort, Conjunctivitis allergic, Cough, Diabetes mellitus, Dyspnoea, Feeling hot, Headache, Hypoventilation, Illness, Injection site reaction, Lower respiratory tract infection, Lung disorder, Myalgia, Nasal congestion, Pain, Perfume sensitivity, Productive cough, Pyrexia, Respiratory tract congestion, Rhinitis, Rhinorrhoea, Seasonal allergy, Smoke sensitivity, Spinal fracture, Upper respiratory tract infection, Wheezing, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, PREDNISONE, MONTELUKAST SODIUM, |
||||
| 748 | 25061969 |
US |
62 | 2 |
Illness, |
||||
TIRZEPATIDE, |
||||
| 749 | 25062028 |
US |
69 | 2 |
Illness, Blood potassium decreased, |
||||
LENALIDOMIDE, |
||||
| 750 | 25062099 |
US |
1 | |
Jaundice, Illness, Chromaturia, Pruritus, Decreased appetite, Asthenia, Emergency care, |
||||
METOPROLOL TARTRATE, METOPROLOL, APIXABAN, |
||||
| 751 | 25062107 |
US |
2 | |
Illness, Product colour issue, Poor quality product administered, Product physical issue, |
||||
| 752 | 25062162 |
US |
21 | 1 |
Illness, Abdominal pain upper, Product physical consistency issue, Drug ineffective, |
||||
LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, |
||||
| 753 | 25062344 |
US |
43 | 2 |
Illness, |
||||
ABATACEPT, |
||||
| 754 | 25062421 |
CZ |
43 | 2 |
Illness, Respiratory tract infection, Gastrointestinal disorder, COVID-19, Nasopharyngitis, |
||||
ADALIMUMAB, |
||||
| 755 | 25062452 |
GB |
2 | |
Lower respiratory tract infection, Illness, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 756 | 25062486 |
CA |
53 | 2 |
Appetite disorder, Arthralgia, Asthenia, Asthma, Blood pressure systolic increased, Body temperature decreased, Breath sounds abnormal, Carpal tunnel syndrome, Chest pain, Cholelithiasis, Cough, Discomfort, Dizziness, Dysphonia, Dyspnoea, Forced expiratory volume decreased, Headache, Hypoaesthesia, Illness, Jaw disorder, Lower respiratory tract infection, Malaise, Nasopharyngitis, Obstructive airways disorder, Poor quality sleep, Procedural pain, Rales, SARS-CoV-2 test positive, Sinusitis, Skin reaction, Stress, Wheezing, Weight decreased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, GLYCOPYRROLATE, MONTELUKAST SODIUM, |
||||
| 757 | 25062826 |
CA |
9 | 1 |
Abdominal pain upper, Asthma, Cough, Drug ineffective, Dyspnoea, Illness, Malaise, Nasopharyngitis, Oropharyngeal pain, Product distribution issue, Tachypnoea, Weight decreased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE FUROATE, FLUTICASONE FUROATE, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 758 | 25062891 |
US |
1 | |
Vomiting, Illness, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 759 | 25063012 |
US |
1 | |
Illness, Asthenia, Bedridden, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 760 | 25063100 |
US |
76 | 2 |
Dysgeusia, Pruritus, Nausea, Ageusia, Alopecia, Rash, Wound, Fatigue, Decreased appetite, Diarrhoea, Illness, Vomiting, |
||||
VISMODEGIB, VISMODEGIB, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 761 | 25063182 |
US |
||
Illness, Nausea, Rash, Diarrhoea, |
||||
NIROGACESTAT, |
||||
| 762 | 25063194 |
US |
2 | |
Chronic obstructive pulmonary disease, Illness, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 763 | 25063231 |
CA |
84 | 1 |
Illness, Lower respiratory tract infection, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 764 | 25063234 |
US |
2 | |
Illness, Intentional dose omission, |
||||
TROFINETIDE, |
||||
| 765 | 25063246 |
CA |
79 | 2 |
Blood pressure diastolic decreased, Blood pressure systolic increased, Urticaria, Illness, Product preparation issue, Product prescribing error, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUPROPION, CANDESARTAN, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, EZETIMIBE, PREDNISONE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, |
||||
| 766 | 25063375 |
CA |
69 | 2 |
Blood pressure increased, Bronchitis, Eye injury, Hypoacusis, Illness, Ligament sprain, Nasopharyngitis, Oedema, Productive cough, Respiratory rate increased, Seasonal allergy, Sputum discoloured, Influenza like illness, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, BUPROPION HYDROCHLORIDE, BUPROPION, BUPROPION HYDROCHLORIDE, BUPROPION, CITALOPRAM, CITALOPRAM HYDROBROMIDE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 767 | 25063392 |
CA |
38 | 2 |
Anxiety, Hypoaesthesia, Hypoaesthesia oral, Illness, Inappropriate schedule of product administration, Joint injury, Mouth swelling, Off label use, Pain, Pruritus, Quality of life decreased, Speech disorder, Swelling face, Urticaria, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, PIMECROLIMUS, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, PREDNISONE, SERTRALINE, |
||||
| 768 | 25063438 |
US |
73 | 2 |
Illness, |
||||
ABATACEPT, |
||||
| 769 | 25063482 |
CA |
14 | 1 |
Hypersensitivity, Illness, Lower respiratory tract infection, Middle insomnia, Obstructive airways disorder, Malaise, Sinus congestion, Asthma, Condition aggravated, Headache, Myalgia, Nausea, Pharyngitis, Sinusitis, Viral infection, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, PREDNISONE, PREDNISONE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 770 | 25063564 |
US |
72 | 1 |
Illness, |
||||
INSULIN LISPRO, |
||||
| 771 | 25063636 |
CA |
23 | 2 |
Bronchitis, COVID-19, Chest discomfort, Cough, Ear pruritus, Fall, Forced expiratory volume decreased, Gastroenteritis viral, Head injury, Hypersensitivity, Illness, Lacrimation increased, Lower respiratory tract infection, Nasopharyngitis, Peripheral swelling, Pulmonary oedema, Pyrexia, Respiratory rate increased, Rhinorrhoea, Secretion discharge, Seizure, Sinus congestion, Sinusitis, Sleep disorder, Swelling, Throat irritation, Urticaria, Weight decreased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, PREDNISONE, ALBUTEROL SULFATE, |
||||
| 772 | 25063670 |
US |
62 | 2 |
Illness, Dysstasia, Gastrointestinal disorder, Nausea, |
||||
AVAPRITINIB, |
||||
| 773 | 25063727 |
CA |
63 | 1 |
Decreased immune responsiveness, Hip arthroplasty, Illness, Muscle rigidity, Pneumonia, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 774 | 25063736 |
CA |
||
Pneumonia, Fall, Head injury, Pain, Illness, Drug ineffective, |
||||
BENRALIZUMAB, LORAZEPAM, PREDNISONE, TIOTROPIUM BROMIDE, MEPOLIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, |
||||
| 775 | 25063864 |
GB |
2 | |
Eye oedema, Headache, Bacterial vaginosis, Central serous chorioretinopathy, Blindness transient, Illness, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 776 | 25063897 |
US |
51 | 2 |
Illness, |
||||
LENALIDOMIDE, |
||||
| 777 | 25063902 |
US |
53 | 2 |
Immune system disorder, Conjunctivitis, Illness, |
||||
ETRASIMOD, |
||||
| 778 | 25063993 |
CA |
28 | 1 |
Arthralgia, Condition aggravated, Illness, Nausea, Diarrhoea, |
||||
METHOTREXATE SODIUM, METHOTREXATE SODIUM, |
||||
| 779 | 25064194 |
US |
||
Pneumonia, Decubitus ulcer, Skin lesion, Intentional dose omission, Illness, |
||||
VUTRISIRAN, |
||||
| 780 | 25064304 |
CA |
43 | 2 |
Angioedema, Blood oestrogen decreased, Ear swelling, Erythema, Illness, Inappropriate schedule of product administration, Lichen planus, Lip swelling, Nasopharyngitis, Peripheral swelling, Product availability issue, Pruritus, Rash, Skin abrasion, Urticaria, Weight decreased, Weight increased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, LORATADINE, LORATADINE TABLET, MEDROXYPROGESTERONE ACETATE, PREDNISONE, PREDNISONE, |
||||
| 781 | 25064322 |
US |
||
Illness, |
||||
| 782 | 25064361 |
CA |
||
Illness, Visual impairment, Dysuria, Incorrect drug administration rate, Accidental overdose, Device infusion issue, |
||||
FLUOROURACIL, FLUOROURACIL, TELMISARTAN, |
||||
| 783 | 25064418 |
CA |
30 | 1 |
Accident at work, Asthma, Blood pressure increased, Bronchitis, COVID-19, Cough, Drug hypersensitivity, Illness, Inappropriate schedule of product administration, Influenza, Malaise, Musculoskeletal pain, Nasal discharge discolouration, Pharyngitis, Product storage error, Productive cough, Sinusitis, Sputum discoloured, Weight increased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, ACLIDINIUM BROMIDE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, LORAZEPAM, FLUTICASONE FUROATE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 784 | 25064476 |
CA |
7 | 2 |
Asthma, Cough, Dust allergy, Frustration tolerance decreased, Gastrointestinal disorder, Illness, Insomnia, Lymphadenitis, Middle insomnia, Nasal congestion, Nasopharyngitis, Oropharyngeal pain, Pyrexia, Respiratory tract infection, Sialoadenitis, Sinusitis, Viral infection, Vomiting, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, AMOXICILLIN, FLUTICASONE FUROATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISONE, ALBUTEROL SULFATE, ALBUTEROL, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 785 | 25064492 |
CA |
44 | 2 |
Angioedema, Asthenia, Dizziness, Dry mouth, Fatigue, Feeling abnormal, Gait disturbance, Hypersomnia, Illness, Malaise, Nausea, Peripheral swelling, Postoperative wound infection, Pruritus, Sedation, Sepsis, Somnolence, Urticaria, Therapeutic product effect decreased, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DOXEPIN, DOXEPIN HYDROCHLORIDE, DOXEPIN, DOXEPIN HYDROCHLORIDE, DOXEPIN, DOXEPIN HYDROCHLORIDE, DOXEPIN, DOXEPIN HYDROCHLORIDE, DOXEPIN, DOXEPIN HYDROCHLORIDE, HYDROXYZINE, DIPHENHYDRAMINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, LORATADINE, LORATADINE TABLET, |
||||
| 786 | 25064519 |
US |
64 | 2 |
Sensitivity to weather change, Sinusitis, Condition aggravated, Pain in extremity, Joint instability, Loss of personal independence in daily activities, Product dose omission issue, Illness, Malaise, |
||||
TOFACITINIB, |
||||
| 787 | 25064538 |
US |
67 | 2 |
Illness, |
||||
GALCANEZUMAB-GNLM, |
||||
| 788 | 25064586 |
US |
||
Pulmonary congestion, Chest discomfort, Feeling hot, Dyspnoea, Feeling abnormal, Drug hypersensitivity, Headache, Visual impairment, Hypoaesthesia, Blood pressure increased, Palpitations, Illness, Head discomfort, Feeling hot, |
||||
RAVULIZUMAB, |
||||
| 789 | 25064937 |
US |
1 | |
Illness, Therapeutic product effect decreased, |
||||
| 790 | 25064957 |
US |
2 | |
Pulmonary congestion, Sinus congestion, Nasal congestion, Illness, |
||||
OFATUMUMAB, |
||||
| 791 | 25065013 |
GB |
||
Mesothelioma, Acute myocardial infarction, Diarrhoea, Malaise, Pyrexia, Platelet count increased, C-reactive protein increased, Inflammation, Illness, Life expectancy shortened, |
||||
TICAGRELOR, |
||||
| 792 | 25065037 |
US |
63 | 1 |
Illness, |
||||
NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, |
||||
| 793 | 25065102 |
US |
37 | 2 |
Pneumonia, Throat irritation, Rhinorrhoea, Cough, Pyrexia, Urinary tract infection, Illness, Fatigue, |
||||
OFATUMUMAB, |
||||
| 794 | 25065123 |
US |
2 | |
Depressed mood, Illness, Fatigue, |
||||
VEDOLIZUMAB, |
||||
| 795 | 25065187 |
CA |
2 | |
Bronchiolitis, Vaginal infection, Dry skin, Headache, Dizziness, Flushing, Grip strength decreased, Muscular weakness, Neck pain, Pain, Hypoaesthesia, Sinusitis, Oropharyngeal pain, Back pain, Drug ineffective, Insomnia, Vision blurred, Rash pruritic, Nasopharyngitis, Fatigue, Cough, Wheezing, Dyspnoea, Illness, Malaise, Product dose omission issue, Inappropriate schedule of product administration, |
||||
METHOTREXATE, METHOTREXATE SODIUM, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE, |
||||
| 796 | 25065230 |
US |
||
Illness, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 797 | 25065365 |
US |
39 | 2 |
Illness, |
||||
BARICITINIB, |
||||
| 798 | 25065654 |
US |
2 | |
Cardiac disorder, Oxygen consumption increased, Migraine, Dizziness, Nausea, Vomiting, Heart rate increased, Malaise, Nasopharyngitis, COVID-19, Balance disorder, Fall, Infusion site swelling, Oxygen saturation decreased, Seasonal allergy, Illness, Diarrhoea, Headache, Infusion site pain, Dyspnoea, Application site pruritus, Application site pain, Infusion site infection, Hypotension, Device malfunction, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, ALBUTEROL SULFATE, AMBRISENTAN, DIPHENHYDRAMINE HYDROCHLORIDE, FUROSEMIDE, NORTRIPTYLINE HYDROCHLORIDE, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, TREPROSTINIL, TADALAFIL, TREPROSTINIL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 799 | 25067617 |
60 | 1 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 800 | 25067685 |
65 | 1 | |
Illness, |
||||
ADALIMUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28